NEW YORK (GenomeWeb News) – Qiagen disclosed in its 2013 annual report filed with the US Securities and Exchange Commission that it acquired CLC Bio for $68.2 million, net of cash acquired. It added in the document that the deal was "not significant" to its overall consolidated financial statements. Qiagen announced the acquisition in October but had not disclosed the financial terms at that time.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.